Back to today’s briefing

Story perspectives

Guardant Health Shares Dip 7.1% Amid Test Concerns

9/6/2025

40 4

Summary

Story summary

Guardant Health's shares dropped 7.1% due to disappointing 13% sensitivity for advanced adenomas in its Shield blood test.
The test showed 84% sensitivity for colorectal cancer and 90% specificity.
Analysts believe the results do not alter the test's long-term outlook.
The stock has experienced a 41% fluctuation over the past year.
It currently trades 11.5% below its 52-week high of $67.42.

1 of 1

Story summary

Guardant Health's shares dropped 7.1% due to disappointing 13% sensitivity for advanced adenomas in its Shield blood test.
The test showed 84% sensitivity for colorectal cancer and 90% specificity.
Analysts believe the results do not alter the test's long-term outlook.
The stock has experienced a 41% fluctuation over the past year.
It currently trades 11.5% below its 52-week high of $67.42.